October 26, 2016: While there were definitely positive things in Biogen’s third-quarter report the company also threw in what almost seemed like an afterthought—it was no longer developing amiselimod (MT-1303).
October 26, 2016: Cempra Pharma is an antibiotic company that I have been following for a long time. The company has a strong pipeline of antibiotics, which are being tested in several different indications.
October 26, 2016: When Novartis shuttered its five-year-old Cell and Gene Therapy Unit in August, it sent shockwaves through the CAR-T community as some believed it to be a signal the company was abandoning the immuno-therapy research program for good.
October 26, 2016: MannKind is in deep trouble. Earlier this year, Sanofi returned the commercial rights for MannKind's only product, inhaled insulin Afrezza, due to an extremely disappointing launch that saw the drug pull in less than $6M in sales during the first nine months of 2015.